Nasdaq4d
Corbus Pharmaceuticals Announces Release of CRB-701 Clinical Study Abstract Ahead of ASCO GU Symposium
Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...
ETF Daily News5d
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
Shares of CRBP stock opened at $9.78 on Monday. The company’s fifty day simple moving average is $12.65 and its two-hundred day simple moving average is $27.00. Corbus Pharmaceuticals has a 52 ...
Business Insider5d
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...
Business Insider5d
Corbus Pharmaceuticals announces clinical data for CRB-701
Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The ...